CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on developing new therapies to protect and regenerate insulin-producing β-cells in diabetes. By targeting the insulin inhibitory receptor and utilizing GLP-1 for safe delivery of estrogen, the aim is to improve β-cell function and potentially reverse diabetes progression without the side effects of…
Glucagon-like peptide 1 (GLP-1) therapy was shown to regenerate β-cells in mice, but this did not translate to human.
Early or intensive insulin therapy maintains residual β-cell function, but also causes weight gain and hypoglycaemia.
Thus, currently no drug treatment can safely stop the progression of diabetes, a disease characterized by loss or dysfunction of insulin-producing β-cells.In breakthrough discoveries we identified the insulin inhibitory receptor (inceptor) as a druggable target fo…
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
